ProCE Banner Activity

CME

Paradigm Shifts in Hemophilia Prophylaxis: Putting Evidence Into Practice

Video

On-demand webcast of expert faculty presentation and case discussion on treatment strategies for hemophilia prophylaxis, including factor replacement therapy, novel nonfactor therapy, and what’s on the horizon, to improve patient outcomes.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 22, 2024

Expiration: April 21, 2025

Share

Faculty

Mark T Reding

Mark T Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Angela C Weyand

Angela C Weyand, MD

Clinical Associate Professor
Co-Director, Pediatric Hematology Gynecology Program
Hemophilia Treatment Center Pediatric Medical Director
Division of Pediatric Hematology Oncology
University of Michigan Medical School
Ann Arbor, Michigan

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Target Audience

This educational program is intended for hematologists and other healthcare professionals who care for patients with hemophilia.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and confidence of learners to optimally integrate new prophylactic therapies into the treatment paradigm for patients with hemophilia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Individualize prophylaxis for patients with hemophilia A with novel factor replacement therapies, considering available evidence, expert recommendations, and patient/caregiver preferences

  • Appraise the mechanisms by which new therapies for hemophilia A and B can restore hemostatic balance

  • Evaluate the available data for investigational nonfactor prophylaxis for hemophilia and their ability to improve patient outcomes without introducing new health risks​

  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: Biomarin, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, Takeda.

Primary Author

Mark T Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Mark T. Reding, MD: consultant/advisor/speaker: Bayer, Biomarin, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda; researcher: Bayer, Biomarin.

Angela C Weyand, MD

Clinical Associate Professor
Co-Director, Pediatric Hematology Gynecology Program
Hemophilia Treatment Center Pediatric Medical Director
Division of Pediatric Hematology Oncology
University of Michigan Medical School
Ann Arbor, Michigan

Angela C. Weyand, MD: consultant/advisor/speaker: Bayer, Biomarin, Genentech, Hemab, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, Takeda; researcher (paid to institution): Novo Nordisk, Pfizer, Sanofi, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2024, through April 21, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.